Magnesium monobenzyl malonate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Magnesium monobenzyl malonate
• 英文别名: magnesium;3-oxo-3-phenylmethoxypropanoate
• 化学式: C20H18MgO8
• 分子量: 410.7
• InChiKey: HWOBBQVNZBIHFX-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -0.64
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  133
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-[[叔丁基二甲基硅烷基]氧基]-戊烷二酸 1-甲基酯 、 Magnesium monobenzyl malonate 以86%的产率得到
  参考文献：
  名称：

  WILLIAMS, M. A.;MILLER, M. J., TETRAHEDRON LETT., 31,(1990) N3, C. 1807-1810

  摘要：

  DOI：

文献信息

• Aminoethanol derivatives
  申请人：——

  公开号：US20040127574A1

  公开（公告）日：2004-07-01

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula 1 wherein Ar 1 is an aromatic ring group optionally having substituents, Ar 2 is an aromatic ring group having substituents, OR″ is an optionally protected hydroxyl group, R is an acyl group, R′ is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药物剂，可用作降低血脂等方面的药物。本发明涉及一种由式1表示的化合物，其中Ar1是一个带有取代基的芳香环基团，Ar2是一个带有取代基的芳香环基团，OR″是一个可选保护的羟基，R是一个酰基，R′是一个氢原子或一个可选带有取代基的碳氢基团，或其盐，以及含有式(I)的化合物或其盐或前药的药物组合物。
• 3(1-hydoxyethyl)azetidinone compounds and their production
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US05134231A1

  公开（公告）日：1992-07-28

  An amino acid compound of the formula: ##STR1## wherein R is a lower alkyl group, R.sub.1 is a hydrogen atom or a protecting group for carboxyl, R.sub.2 is a hydrogen atom, a protecting group for amino, an optionally substituted allyl group of the formula: ##STR2## (wherein R.sub.3 and R.sub.4 are each a hydrogen atom, a lower alkyl group or an aryl group), a beta-hydroxyethyl group in which the hydroxyl group is optionally protected, a formylmethyl group in which the formyl group is optionally protected, a carboxymethyl group in which the carboxyl group is protected or a 2-furylmethyl group and X is an optionally protected carboxyl group, a hydroxymethyl group in which the hydroxyl group is optionally protected or a substituted mercaptomethyl group of the formula: --CH.sub.2 SR.sub.5 (wherein R.sub.5 is an aryl group or an ar(lower)alkyl group), which is a useful intermediate in the synthesis of 1-alkylcarbapenem compounds.

  化合物的氨基酸式：##STR1## 其中R是低碳基团，R.sub.1是羧基的保护基或氢原子，R.sub.2是氨基的保护基、可选取代的烯丙基式：##STR2##（其中R.sub.3和R.sub.4分别是氢原子、低碳基团或芳基团），β-羟乙基基团，其中羟基可以选择性保护，甲酰甲基基团，其中甲酰基可以选择性保护，羧甲基基团，其中羧基被保护或2-呋喃甲基基团，X是可选择性保护的羧基，羟甲基基团，其中羟基可以选择性保护，或取代的巯基甲基基团式：--CH.sub.2 SR.sub.5（其中R.sub.5是芳基团或芳(低)碳基团），该化合物是1-烷基卡巴冬烯类化合物合成中有用的中间体。
• (1R,5S,6S)-2-(substituted thio)-6-[(R)-1-hydroxy-ethyl]-1-methyl-carbapenem-3-carboxylic-acid derivatives
  申请人：LEDERLE (JAPAN) LTD.

  公开号：EP0289801A1

  公开（公告）日：1988-11-09

  Novel carbapenem compounds, (1R,5S,6S)-2-­substituted thio-6-[(R)-1-hydroxyethyl]-1-methyl-­carbapenem-3-carboxylic acid derivatives. These carbapenem compounds are represented by the following formula having a beta-coordinated methyl group introduced into the 1-position and a 4-pyrazol­izinylthio group or a 6,7-dihydro-5H-pyrazolo[1,2-a]­[1,2,4]triazolium-6-ylthio group introduced into the 2-position. In the formula, R¹ represents a radical of the formula     and R² is a hydrogen atom or an anion charge. They have antibacterial activity, and are used for pre­vention and treatment of bacterial infections as anti­bacterial agents. A process for producing these carba­penem compounds is also provided.

  新型碳青霉烯化合物，(1R,5S,6S)-2-取代硫-6-[(R)-1-羟乙基]-1-甲基碳青霉烯-3-羧酸衍生物。 这些碳青霉烯化合物由下式表示，其 1-位引入了一个β-配位甲基，2-位引入了一个 4-吡唑嗪硫基或一个 6,7-二氢-5H-吡唑并[1,2-a][1,2,4]三唑鎓-6-硫基。 式中，R¹ 代表式中的一个基团 和 R² 是氢原子或阴离子电荷。它们具有抗菌活性，可作为抗菌剂用于预防和治疗细菌感染。此外，还提供了生产这些碳青霉烯类化合物的工艺。
• PYRIDYLPYRROLE DERIVATIVES
  申请人：Sankyo Company Limited

  公开号：EP1031572A1

  公开（公告）日：2000-08-30

  Object: to provide compounds having an inhibitory effect on the production of inflammatory cytokines. Constitution: compounds having general formula (I), pharmacologically acceptable salts thereof or derivatives of the same, wherein A: single bond, oxygen, sulfur, CO, SO, SO2, C(R9)(R10) [R9, R10: H, OH, halogeno, alkyl], N(R11), C=NOR11 [R11: H, alkyl]; D: single bond, C(R12)(R13) [R12, R13: H, OH, halogeno, alkyl]; R1 : optionally substituted pyridyl; R2 : optionally substituted phenyl; R3 : halogeno, alkyl, haloalkyl, alkoxy, haloalkoxy; R4, R5, R6, R7, R8 : H, alkyl; k: 0-3; and m: 1, 2.

  目的：提供对炎症细胞因子的产生具有抑制作用的化合物。构成：具有通式（I）的化合物、其药理学上可接受的盐或其衍生物，其中A：单键、氧、硫、CO、SO、SO2、C(R9)(R10)[R9、R10：H、OH、卤代、烷基]、N(R11)、C=NOR11[R11：H、烷基]；D：单键、C(R12)(R13) [R12、R13：H、OH、卤代物、烷基]；R1：任选取代的吡啶基；R2：任选取代的苯基；R3：卤代物、烷基、卤代烷基、烷氧基、卤代烷氧基；R4、R5、R6、R7、R8：H、烷基；k：0-3；m：1、2。
• AMINOETHANOL DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1362846A1

  公开（公告）日：2003-11-19

  The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

  本发明提供了一种具有胆固醇酯转移蛋白抑制作用的药剂，可用作降血脂药等。本发明涉及一种由式表示的化合物 其中 Ar1 是可选具有取代基的芳香环基，Ar2 是可选具有取代基的芳香环基，OR''是可选保护的羟基，R 是酰基，R'是氢原子或可选具有取代基的烃基，或其盐，以及含有式（I）化合物或其盐或其原药的药物组合物。